Barton Paschal
Medical Oncology · Clyde, NCNPI 1063452506
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations.
Across 152 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$251
- Novartis$232
- Genentech USA, Inc.$215
- Pfizer$181
- Amgen$152
- Bayer$134
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,25699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 22 | $251 |
| Novartis | 12 | $232 |
| Genentech USA, Inc. | 14 | $215 |
| Pfizer | 15 | $181 |
| Amgen | 10 | $152 |
| Bayer | 10 | $134 |
| Eisai Inc. | 7 | $126 |
| Bristol Myers Squibb | 6 | $111 |
| AstraZeneca(2 entities) | 6 | $104 |
| Astellas Pharma US Inc | 4 | $63 |
| Exelixis Inc. | 4 | $63 |
| Rigel Pharmaceuticals, Inc. | 3 | $57 |
| Merck | 4 | $55 |
| Sanofi | 3 | $53 |
| Incyte Corporation | 3 | $53 |
| Gilead | 3 | $49 |
| Taiho Oncology, Inc. | 3 | $44 |
| Johnson & Johnson | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $43 |
| Seagen Inc. | 3 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| EMD Serono, Inc. | 2 | $26 |
| Puma Biotechnology, Inc. | 2 | $23 |
| AbbVie | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Fortovia Therapeutics, Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $11 |
How this compares
$2,268 in reported general payments places this provider in the 60th percentile of 170 medical oncology providers in North Carolina.
Other medical oncology in Clyde
- Thomas LeblancDurham$1.7M
- David RizzieriCharlotte$714K
- Raghava InduruAlbemarle$625K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Andrew ArmstrongDurham$377K
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Thomas StinchcombeChapel Hill$281K
- Steven SorscherWinston Salem$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.